Literature DB >> 21947468

Threshold of soluble fms-like tyrosine kinase 1/placental growth factor ratio for the imminent onset of preeclampsia.

Akihide Ohkuchi1, Chikako Hirashima, Shigeki Matsubara, Kayo Takahashi, Yoshio Matsuda, Mitsuaki Suzuki.   

Abstract

It has not been clarified whether thresholds of soluble fms-like tyrosine kinase 1 (sFlt-1), placental growth factor (PlGF), soluble endoglin, and the sFlt-1/PlGF ratio for the imminent onset of preeclampsia (PE) exist. We hypothesized that onset thresholds for the imminent onset of PE could be determined by the distributions of these 4 markers just after the onset of PE. Study subjects were 51 PE after the onset of PE; 36 of PE, 20 of gestational hypertension, 142 of a small-for-gestational-age infant, and 400 of normal pregnant controls at 19 to 25 and 27 to 31 weeks of gestation in a prospective cohort study. The current data supported our hypothesis that onset thresholds of sFlt-1 and the sFlt-1/PlGF ratio exist. The onset thresholds of the sFlt-1/PlGF at 26 to 31 weeks of gestation were useful for detecting imminent PE with the onset at <36 weeks of gestation, showing sensitivity of 0.36 and a positive likelihood ratio and 95th percent CIs of 38 (11-132); when positive, PE occurred at 2.2±0.6 weeks (range: 1.4-3.0 weeks) after the measurement of the sFlt-1/PlGF ratio. The combination of sFlt-1 at 26 to 31 weeks of gestation, past history of gestational hypertension or PE, prepregnancy body mass index, and mean blood pressure at 16 to 23 weeks of gestation was useful for detecting PE with onset of <36 weeks of gestation, showing sensitivity of 0.82, and a positive likelihood ratio (95% CI) of 42 (20-88). In conclusion, the onset threshold of sFlt-1/PlGF existed and might be useful for detecting the imminent onset of PE.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21947468     DOI: 10.1161/HYPERTENSIONAHA.111.174417

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  11 in total

1.  Increased antiangiogenetic factors in severe proteinuria without hypertension in pregnancy: is kidney biopsy necessary?

Authors:  Takako Ohmaru; Akihide Ohkuchi; Shigeaki Muto; Chikako Hirashima; Shigeki Matsubara; Mitsuaki Suzuki
Journal:  CEN Case Rep       Date:  2013-08-23

2.  AICAR administration ameliorates hypertension and angiogenic imbalance in a model of preeclampsia in the rat.

Authors:  Christopher T Banek; Ashley J Bauer; Karen M Needham; Hans C Dreyer; Jeffrey S Gilbert
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-02-15       Impact factor: 4.733

3.  Prediction and prevention of hypertensive disorders of pregnancy.

Authors:  Akihide Ohkuchi; Chikako Hirashima; Kayo Takahashi; Hirotada Suzuki; Shigeki Matsubara
Journal:  Hypertens Res       Date:  2016-08-18       Impact factor: 3.872

4.  Difficulty of predicting early-onset super-imposed preeclampsia in pregnant women with hemodialysis due to diabetic nephropathy by serum levels of sFlt-1, PlGF, and sEng.

Authors:  Hiroyuki Morisawa; Chikako Hirashima; Miho Sano; Shiho Nagayama; Hironori Takahashi; Koumei Shirasuna; Akihide Ohkuchi
Journal:  CEN Case Rep       Date:  2019-11-14

5.  Removal of Soluble Fms-Like Tyrosine Kinase-1 by Dextran Sulfate Apheresis in Preeclampsia.

Authors:  Ravi Thadhani; Henning Hagmann; Wiebke Schaarschmidt; Bernhard Roth; Tuelay Cingoez; S Ananth Karumanchi; Julia Wenger; Kathryn J Lucchesi; Hector Tamez; Tom Lindner; Alexander Fridman; Ulrich Thome; Angela Kribs; Marco Danner; Stefanie Hamacher; Peter Mallmann; Holger Stepan; Thomas Benzing
Journal:  J Am Soc Nephrol       Date:  2015-09-24       Impact factor: 10.121

6.  Recent advances in the understanding of the pathophysiology of preeclampsia.

Authors:  Junie P Warrington; Eric M George; Ana C Palei; Frank T Spradley; Joey P Granger
Journal:  Hypertension       Date:  2013-07-29       Impact factor: 10.190

7.  Second-trimester urine nephrin:creatinine ratio versus soluble fms-like tyrosine kinase-1:placental growth factor ratio for prediction of preeclampsia among asymptomatic women.

Authors:  Tianyue Zhai; Itsuko Furuta; Kinuko Nakagawa; Takashi Kojima; Takeshi Umazume; Satoshi Ishikawa; Takahiro Yamada; Mamoru Morikawa; Hisanori Minakami
Journal:  Sci Rep       Date:  2016-11-22       Impact factor: 4.379

8.  Of risks and ratios: the usefulness of angiogenic balance for diagnosing preeclampsia at different gestational ages.

Authors:  Jeffrey S Gilbert; Sara A Babcock; Ronald R Regal; Jean F Regal
Journal:  Hypertension       Date:  2013-10-28       Impact factor: 10.190

9.  Placental Growth Factor Reduces Blood Pressure in a Uteroplacental Ischemia Model of Preeclampsia in Nonhuman Primates.

Authors:  Angela Makris; Kristen R Yeung; Shirlene M Lim; Neroli Sunderland; Scott Heffernan; John F Thompson; Jim Iliopoulos; Murray C Killingsworth; Jim Yong; Bei Xu; Robert F Ogle; Ravi Thadhani; S Ananth Karumanchi; Annemarie Hennessy
Journal:  Hypertension       Date:  2016-04-18       Impact factor: 10.190

10.  Plasma concentrations of soluble endoglin versus standard evaluation in patients with suspected preeclampsia.

Authors:  Sarosh Rana; Ana Sofia Cerdeira; Julia Wenger; Saira Salahuddin; Kee-Hak Lim; Steven J Ralston; Ravi I Thadhani; S Ananth Karumanchi
Journal:  PLoS One       Date:  2012-10-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.